Get started
Oryzon Genomics SAOryzon Genomics SAOryzon Genomics SA

Oryzon Genomics SA

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonals

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪286.88 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.05 USD
Net income (FY)
‪−3.79 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪60.02 M‬
Beta (1Y)
0.27

Employees


Employees (FY)
46
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−82.49 K‬ USD

About Oryzon Genomics SA


Sector
Health Technology
Industry
Biotechnology
CEO
Carlos Manuel Buesa Arjol
Website
oryzon.com
Headquarters
Barcelona
Founded
2000
IPO date
Dec 10, 2015
Identifiers
2
ISIN ES0167733015
Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. It focuses on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative disease. The firm's product pipelines include Iadademstat and Vafidemstat. The company was founded by Carlos Manuel Buesa Arjol and Tamara Maes on June 2, 2000 and is headquartered in Barcelona, Spain.

Check out other big names from the same industry as ORYZF.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ORYZF is 3.60 USD — it has increased by 7.14% in the past 24 hours. Watch Oryzon Genomics SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Oryzon Genomics SA stocks are traded under the ticker ORYZF.
We've gathered analysts' opinions on Oryzon Genomics SA future price: according to them, ORYZF price has a max estimate of 14.22 USD and a min estimate of 4.74 USD. Watch ORYZF chart and read a more detailed Oryzon Genomics SA stock forecast: see what analysts think of Oryzon Genomics SA and suggest that you do with its stocks.
ORYZF reached its all-time high on Jun 18, 2021 with the price of 4.77 USD, and its all-time low was 1.41 USD and was reached on Apr 16, 2024. View more price dynamics on ORYZF chart.
See other stocks reaching their highest and lowest prices.
ORYZF stock is 6.67% volatile and has beta coefficient of 0.27. Track Oryzon Genomics SA stock price on the chart and check out the list of the most volatile stocks — is Oryzon Genomics SA there?
Today Oryzon Genomics SA has the market capitalization of ‪286.88 M‬, it has increased by 1.50% over the last week.
Yes, you can track Oryzon Genomics SA financials in yearly and quarterly reports right on TradingView.
Oryzon Genomics SA is going to release the next earnings report on Mar 2, 2026. Keep track of upcoming events with our Earnings Calendar.
ORYZF earnings for the last quarter are −0.01 USD per share, whereas the estimation was −0.01 USD resulting in a −1.04% surprise. The estimated earnings for the next quarter are −0.04 USD per share. See more details about Oryzon Genomics SA earnings.
Oryzon Genomics SA revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪1.64 M‬ USD. In the next quarter, revenue is expected to reach ‪2.23 M‬ USD.
ORYZF net income for the last quarter is ‪395.17 K‬ USD, while the quarter before that showed ‪121.73 K‬ USD of net income which accounts for 224.64% change. Track more Oryzon Genomics SA financial stats to get the full picture.
No, ORYZF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 14, 2026, the company has 46 employees. See our rating of the largest employees — is Oryzon Genomics SA on this list?
Like other stocks, ORYZF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oryzon Genomics SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Oryzon Genomics SA technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Oryzon Genomics SA stock shows the buy signal. See more of Oryzon Genomics SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.